What is EicOsis?
EicOsis is a biopharmaceutical company dedicated to creating innovative, non-addictive oral analgesics and anti-inflammatories. Their therapeutic approach targets the soluble Epoxide Hydrolase (sEH) enzyme, aiming to leverage the body's inherent healing mechanisms. The company is addressing a critical unmet need for effective chronic pain management solutions, particularly in the context of the widespread opioid crisis. EicOsis's lead drug candidate is currently progressing through Phase 1 clinical trials, with ongoing research exploring its potential across a spectrum of pain-related conditions.
How much funding has EicOsis raised?
EicOsis has raised a total of $4M across 1 funding round:
Private Equity
$4M
Private Equity (2016): $4M, investors not publicly disclosed
What's next for EicOsis?
The substantial enterprise-level backing and recent strategic investment position EicOsis for a pivotal phase of growth and clinical advancement. This capital infusion is anticipated to fuel the progression of their sEH inhibitor program through further clinical trials, potentially leading to regulatory submissions. Strategic partnerships and continued research into diverse pain indications will likely be key priorities as EicOsis aims to establish a significant presence in the pain management market and offer a safer alternative to existing opioid-based therapies.
See full EicOsis company page
